TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR-mutated lung cancer

Ritsu Ibusuki(Kyushu University), Isamu Okamoto(Kyushu University Hospital)
npj Precision Oncology
March 2, 2024
Cited by 36


Related Papers